US policy pressure is building around outbound capital flows into China biotech, with lawmakers urging restrictions. A GOP lawmaker asked the Trump administration to curb China biotech deals, arguing that heightened scrutiny should apply to investment streams that feed the sector. The request sits alongside calls within the broader policy debate for extending outbound investment bans. For companies and investors, it raises the prospect of deal re-structuring, compliance overhead, and altered partnership timelines tied to China exposure. The policy focus matters for sector execution because it can directly affect cross-border financings, technology collaborations, and market access strategies for US-based biotech backers.